Scarica l'app Stockscreener
66.28
0.87%
0.57
Pre-mercato:
67.43
1.15
+1.74%
Precedente Chiudi:
$65.71
Aprire:
$65.85
Volume 24 ore:
4.25M
Relative Volume:
2.43
Capitalizzazione di mercato:
$12.96B
Reddito:
$579.96M
Utile/perdita netta:
$-729.89M
Rapporto P/E:
-17.69
EPS:
-3.7459
Flusso di cassa netto:
$-452.02M
1 W Prestazione:
-1.53%
1M Prestazione:
-18.24%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$65.33
$67.30
Intervallo di 1 settimana:
$64.90
$70.00
Portata 52W:
$64.90
$89.49
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
66.28 | 12.96B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
101.07 | 174.89B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.51 | 113.22B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
269.75 | 103.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.68 | 64.75B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 49.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Borsa (BBIO) Ultime notizie
BIO: Multi-year transformation leverages technology, M&A, and restructuring to drive growth and margin expansion - TradingView
BIO: Multi-year transformation leverages digital PCR leadership and targeted M&A for growth - TradingView
Bio-Rad at bernstein healthcare forum: shift toward profitable growth - Investing.com
Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - GuruFocus
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - finance.yahoo.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - quiverquant.com
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - The Manila Times
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - finance.yahoo.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Challenges in the Medical Devices Sector - DirectorsTalk Interviews
Bio-rad Laboratories Stock Price Forecast. Should You Buy BIO? - StockInvest.us
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - finance.yahoo.com
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues - Yahoo Finance
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - manufacturingchemist.com
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories (BIO) Edges Lower to $388.77 as Shares Consolidate Between Key Support and ResistanceWyckoff Upthrust - careplusvn.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - directorstalkinterviews.com
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Move: Finishes 0.71% Lower at $373.79 on the Day; Key Range: the Session Ends Within the Reported Technical Boundaries on the DayBlue Chip Entry Points - careplusvn.com
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio Rad Laboratories Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.31%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):